Using E3 ligases to develop new cancer therapies
Harnessing E3 Ligases for Cancer Therapy
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA BERKELEY · NIH-10913762
This study is looking at a new way to help fight cancer by using special tiny molecules to help the body get rid of harmful proteins that cause cancer, which are usually hard to target with regular treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA BERKELEY (nih funded) |
| Locations | 1 site (BERKELEY, UNITED STATES) |
| Trial ID | NIH-10913762 on ClinicalTrials.gov |
What this research studies
This research focuses on targeted protein degradation (TPD) as a method to eliminate cancer-causing proteins that are typically difficult to target with conventional therapies. By utilizing small molecules to bring E3 ubiquitin ligases into close proximity with these proteins, the research aims to enhance the degradation of harmful proteins associated with cancer. The team will explore innovative strategies to improve the effectiveness of TPD, including the design of new molecular glue degraders and identifying suitable E3 ligases for therapeutic applications. This approach could potentially lead to breakthroughs in treating various cancers by targeting previously undruggable proteins.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers driven by undruggable oncogenic transcription factors or other specific protein targets.
Not a fit: Patients whose cancers are not associated with the targeted proteins or who have already exhausted all available treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective cancer treatments that specifically target and eliminate harmful proteins.
How similar studies have performed: Previous research has shown promise in targeted protein degradation approaches, indicating potential for success in this innovative area of cancer therapy.
Where this research is happening
BERKELEY, UNITED STATES
- UNIVERSITY OF CALIFORNIA BERKELEY — BERKELEY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NOMURA, DANIEL — UNIVERSITY OF CALIFORNIA BERKELEY
- Study coordinator: NOMURA, DANIEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents